• Profile
Close

Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease

Kidney International Apr 13, 2019

Schlackow I, et al. - Researchers evaluated the impact of statins and ezetimibe on quality-adjusted life years (QALYs) and health care costs in the patients with non-dialysis-dependent chronic kidney disease (CKD) in the United States (US) and the United Kingdom (UK), by using the Study of Heart and Renal Protection (SHARP) CKD-CVD (cardiovascular disease) policy model. They defined cost-effectiveness as net costs below $100,000/QALY (US) or £20,000/QALY (UK). In non-dialysis patients with stages 3B to 5 CKD in the US, an increase in life expectancy by 0.23 to 0.31 QALYs was noted with atorvastatin 40 mg ($0.103/day as of January 2019), at a net cost of $20,300 to $78,200/QALY. With the addition of ezetimibe 10 mg ($0.203/day), an increase in life expectancy by an additional 0.05 to 0.07 QALYs was reported, at a net cost of $43,600 to $91,500/QALY. Overall, statin/ezetimibe combination therapy was cost-effective in attenuating CVD risk in patients with non-dialysis-dependent CKD.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay